Outcome of Innate Pharma's 2026 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.

Business Wire • May 22, 2026

Innate Pharma to participate in the Jefferies Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to Participate in the Jefferies Global Healthcare Conference.

Business Wire • May 19, 2026

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer.

MarketBeat • May 13, 2026

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the quarter ending March 31, 2026. “We have continued to make solid progress across our priority clinical assets during the first quarter. We are approaching completion of enrollment in the Phase 1 dose escalation and backfill cohorts for IPH4502. In parallel, we have advanced the negotiati.

Business Wire • May 13, 2026

Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026.

Business Wire • May 12, 2026

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and webcast for Q1 2026 Business Update.

Business Wire • May 6, 2026

Innate Pharma to Participate in the D. Boral Capital Global Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital Global Conference.

Business Wire • Apr 23, 2026

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22.

Business Wire • Apr 17, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 9, 2026.

Business Wire • Apr 13, 2026